BOSTON, MA / ACCESSWIRE / April 24, 2024 / Hop On A Cure, a leading advocate in the fight against ALS, has announced today their financial contribution of $250,000 toward Massachusetts General Hospital Department of Neurology's Sean M. Healey & AMG Center for ALS.
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced two research collaborations with Massachusetts General Hospital (MGH), the largest hospital-based research program in the U.S. that delivers care grounded in leading-edge research, advanced treatment offerings and the latest clinical trials. The collaborations are designed to explore the role of tumor genetics and the tumor microenvironment of patients with follicular lymphoma (FL) and to understand their impact on disease transformation and response to treatment.
In Alzheimer’s disease, an overactive immune system kills off neuronal cells, leading to dementia. Now, scientists at Massachusetts General Hospital have pinpointed a protein involved in immune signaling they believe plays a key role in the progression of the disease.